These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9114522)

  • 21. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors.
    Colombo R; Da Pozzo LF; Lev A; Salonia A; Rigatti P; Leib Z; Servadio C; Caldarera E; Pavone-Macaluso M
    J Urol; 1998 Mar; 159(3):783-7. PubMed ID: 9474148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT; Soloway MS
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Intravesical therapy: Influence on superficial bladder cancer progression].
    García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; Alvarez Múgica M; Rodríguez Robles L; Martín Benito JL; San Martín Blanco A; Regadera Sejas J
    Arch Esp Urol; 2007; 60(1):31-5. PubMed ID: 17408169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer.
    Tran E; Souhami L; Tanguay S; Rajan R
    Am J Clin Oncol; 2009 Aug; 32(4):333-7. PubMed ID: 19381080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
    Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
    J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience.
    Serretta V; Lo Greco G; Pavone C; Pavone-Macaluso M
    J Urol; 1998 Apr; 159(4):1187-91. PubMed ID: 9507829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Minimally invasive therapy for bladder and prostate cancer].
    Uchida T; Ohori M; Egawa S
    Gan To Kagaku Ryoho; 2001 Aug; 28(8):1094-8. PubMed ID: 11525024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The management of superficial bladder cancer.
    Dalbagni G
    Nat Clin Pract Urol; 2007 May; 4(5):254-60. PubMed ID: 17483810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer.
    Hendricksen K; Witjes JA
    Curr Opin Urol; 2007 Sep; 17(5):352-7. PubMed ID: 17762630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular alterations associated with bladder cancer progression.
    Sánchez-Carbayo M; Cordon-Cardó C
    Semin Oncol; 2007 Apr; 34(2):75-84. PubMed ID: 17382791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases.
    Engeler DS; Wyler S; Neyer M; Hobi C; Müller J; Schmid HP
    Scand J Urol Nephrol; 2008; 42(6):522-7. PubMed ID: 18609290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of care for the treatment of bladder cancer.
    Snyder C; Harlan L; Knopf K; Potosky A; Kaplan R
    J Urol; 2003 May; 169(5):1697-701. PubMed ID: 12686811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follow-up of nonmuscle invasive transitional cell carcinoma of the bladder: how and how often?
    Schmidbauer J; Lindenau G
    Curr Opin Urol; 2008 Sep; 18(5):504-7. PubMed ID: 18670275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perioperative instillation therapy in superficial bladder cancer: is it effective regarding outcome and costs?
    Engel RP; Witjes JA
    Curr Opin Urol; 2009 Sep; 19(5):511-5. PubMed ID: 19553821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Bladder cancer: realities and perspectives].
    Chrétien Y; Oudard S; Durdux C
    Bull Cancer; 2003 Jan; 90(1):61-7. PubMed ID: 12609806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.
    Hendricksen K; Gleason D; Young JM; Saltzstein D; Gershman A; Lerner S; Witjes JA
    J Urol; 2008 Jul; 180(1):116-20. PubMed ID: 18485407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.